期刊文献+

PTEN及mTOR在人肺腺癌培美曲塞耐药株A549/PEM中的表达 被引量:6

The expression and significance of PTEN and mTOR in A549 and pemetrexed-resistant human lung adenocarcinoma cancer cell line A549
下载PDF
导出
摘要 目的:应用高浓度反复间歇法建立人肺腺癌A549培美曲塞耐药细胞株A549/PEM,探讨PTEN、m TOR在人肺腺癌亲本株A549及培美曲塞诱导人肺腺癌耐药株A549/PEM中的表达变化。方法:采用终浓度为500ng/ml的培美曲塞反复间歇冲击建立人肺腺癌A549培美曲塞耐药细胞株A549/PEM,MTT法检测细胞耐药性。RT-PCR、Western blot分别检测PTEN、m TOR在A549及A549/PEM细胞的mRNA及蛋白表达变化。结果:A549/PEM耐药指数为26.87±1.81,较亲本株A549升高约27倍。RT-PCR检测mRNA表达示A549/PEM的PTEN及m TOR基因表达与A549相比均表达上调(P=0.023;P<0.01);Western blot检测蛋白表达示A549/PEM的PTEN及m TOR蛋白表达与A549相比均表达上调(P<0.01;P=0.04)。结论:高浓度反复间歇法可成功建立人肺腺癌A549培美曲塞耐药细胞株模型;PTEN、m TOR表达变化可能与培美曲塞获得性耐药相关。 Objective:To establish the pemetrexed-resistant human lung adenocarcinoma cancer cell line A549 by exposing lung adenocarcinoma cancer cell line A549 with repeatedly high-level concentration of pemetrexed,and investigate the expression of PTEN and mTOR in normal lung adenocarcinoma cancer cell line A549 and pemetrexed-resistant human lung adenocarcinoma cancer cell line A549/PEM.Methods:The pemetrexed-resistant human lung adenocarcinoma cancer cell line A549/PEM was established by exposing pemetrexed with repeatedly to high-level concentration of 500ng/ml for 1h each time.The drug resistant index(RI) was detected by MTT.The expression of PTEN and mTOR in A549 and A549/PEM were detected by RT-PCR and Western blot.Results:The value of resisitant index of A549/PEM was elevated more than 27 times,the number was 26.87±1.81.Over-expression mRNA and protein of PTEN in A549/PEM were detected by RT-PCR and Western blot(P=0.023,P〈0.01).Over-expression mRNA and protein of mTOR in A549/PEM was detected by RT-PCR and Western Blot (P〈0.01;P=0.04).Conclusion:The pemetrexed-resistant human lung adenocarcinoma cancer cell line A549 can be established by repeated exposing to high-level concentration of pemtrexed successfully.The variation of PTEN and mTOR may be connected with lung adenocarcinoma pemetrexed acquired drug resistance.
出处 《现代肿瘤医学》 CAS 2016年第3期343-346,共4页 Journal of Modern Oncology
基金 河北省卫生重点科技研究计划(编号:ZD20140302)
关键词 PTEN m TOR 培美曲塞 耐药 A549 A549/PEM PTEN, mTOR, pemetrex, acquired drug resistance, A549, A549/PEM
  • 相关文献

参考文献3

二级参考文献153

  • 1Lee S,Choi EJ,Jin C,et al.Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line[J].Gynecol Oncol,2005,97(1):26-34.
  • 2Osaki M,Oshimura M,Ito H.PI3K-Akt pathway:its functions and alterations in human cancer[J].Apoptosis,2004,9(6):667-676.
  • 3Jemal A,Siegel R,Ward E,et al.Cancer statistics,2009[J].CA Cancer J Clin,2009,59(4):225-249.
  • 4Boeck S,Weigang-Khler K,Fuchs M,et al.Second-line chemotherapy with pemetrexed after gemcitabine failure in patients with advanced pancreatic cancer:a multicenter phase II trial[J].Ann Oncol,2007,18(4):745-751.
  • 5Downes CP,Perera N,Ross S,et al.Substrate specificity and acute regulation of the tumour suppressor phosphatase,PTEN[J].Biochem Soc Symp,2007,(74):69-80.
  • 6Fresno Vara JA,Casado E,de Castro J,et al.PI3K/Akt signalling pathway and cancer[J].Cancer Treat Rev,2004,30(2):193-204.
  • 7Li H,Yu JP,Cao J,et al.Effect of PI3K/AKt inhibitor on the expression of Caspase-9 in human gastric cancer cells[J].Med J Wu han Univ,2008,29(1):38-40.
  • 8Kim SH,Juhnn YS,Song YS.Akt involvement in paclitaxel chemoresistance of human ovarian cancer cells[J].Ann N Y Acad Sci,2007,1095:82-89.
  • 9LoPiccolo J,Blumenthal GM,Bernstein WB,et al.Targeting the PI3K/Akt/mTOR pathway:effective combinations and clinical considerations[J].Drug Resist Update,2008,11(1-2):32-50.
  • 10Kim RH,Peters M,Jang Y,et al.DJ-1,a novel regulator of the tumor suppressor PTEN[J].Cancer Cell,2005,7(3):263-273.

共引文献14

同被引文献73

引证文献6

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部